Monopar Therapeutics (MNPR) intrinsic value & 10-year financials
Monopar Therapeutics (MNPR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -1163.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $69.27
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -1163.8%
- Free cash flow (FY2025)
- —
MNPR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$13.7M | — | — | — | -39.1% |
| FY2024 | $0 | -$15.6M | — | — | — | -428.6% |
| FY2023 | $0 | -$8.4M | — | — | — | -7562.5% |
| FY2022 | — | -$10.5M | — | — | — | -3838.1% |
| FY2021 | — | -$9.1M | — | — | — | 669.7% |
| FY2020 | — | -$6.3M | — | — | — | -46.0% |
| FY2019 | $0 | -$4.2M | — | — | — | -44.2% |
| FY2018 | $0 | -$3.2M | — | — | — | -40.3% |
| FY2017 | $0 | -$16.6M | — | — | — | -266.6% |
| FY2016 | $0 | -$1.2M | — | — | — | -42.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Monopar Therapeutics revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Monopar Therapeutics has historically struggled to out-earn its cost of capital, averaging just -32.6% ROIC.
Monopar Therapeutics capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Monopar Therapeutics is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.